919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut).
Saved in:
| Title: | 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). |
|---|---|
| Authors: | Ferrarotto, R.1 (AUTHOR), Wirth, L.J.2 (AUTHOR), Muzaffar, J.3 (AUTHOR), Rodriguez, C.P.4 (AUTHOR), Xia, B.5 (AUTHOR), Perez, C.A.6 (AUTHOR), Bowles, D.W.7 (AUTHOR), Winquist, E.8 (AUTHOR), Hotte, S.J.9 (AUTHOR), Metcalf, R.10 (AUTHOR), Even, C.11 (AUTHOR), Gordon, G.B.12 (AUTHOR), Gordon, G.12 (AUTHOR), Ho, A.13 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS663-S663. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.1034 |
